Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Sepsis-induced Cardiomyopathythe Recovery Phase of Septic Shock
Interventions
DRUG

Lyophilized Recombinant Human Brain Natriuretic Peptide

rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. Patients should receive at least the first 500μg dose infusion, with a recommended duration of 72 hours. The specific timing of discontinuation will be determined by the attending physician. Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.

All Listed Sponsors
collaborator

Tibet Kangzhe Pharmaceutical Development Co., Ltd

UNKNOWN

lead

Sichuan Provincial People's Hospital

OTHER

NCT06745206 - Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock | Biotech Hunter | Biotech Hunter